## Nominations for the addition/removal of a drug or device to be excluded from national payment system prices

Within the National Tariff Payment System,[[1]](#footnote-1) some high cost drugs and devices are excluded from the calculation of unit prices and national prices. Funding for these items is then either included in a fixed payment or paid for in addition to the price for the related service.

As medical practice changes and new drugs and devices are developed and adopted, the lists of high cost drugs and devices needs to be kept as current as practically possible, requiring input from the health sector for changes to the lists.

The table overleaf should be completed and used to submit nominations for additions to, and removals from, the high cost drugs and devices lists for the next national tariff. All submissions will be reviewed by the high cost drugs or high cost devices steering groups.

When considering which items to include in the lists for the next national tariff, our guiding principle is that the drug or device should be high cost and represent a disproportionate cost compared to the other expected costs of care within the Healthcare Resource Group (HRG) or Treatment Function Code (TFC) which would affect fair reimbursement. We recognise, however, that for some new drugs or devices it can be difficult to produce cost and usage estimates, and so we will consider all relevant information available that will help to inform recommendations. We also recognise that there may be circumstances where it is beneficial to the service to add or retain devices on the high cost list in order to support procurement arrangements introduced by NHS England Specialised Commissioning.

We would expect nominations for drugs or devices to be added to the lists to relate to items that are either not currently in use or have only recently come into use.

For nominations to be considered for the 2023/24 national tariff, please ensure the completed form is submitted by **31 May 2022**. Any submissions received after that date may be considered for a future tariff.

Please complete the table overleaf and send it to [pricing@england.nhs.uk](mailto:pricing@england.nhs.uk)

### Form: nomination for change to high cost drugs and devices list

|  |  |
| --- | --- |
| Date of submission: |  |
| Name: |  |
| Organisation that you represent: |  |
| Job title/role in your organisation: |  |
| Email address: |  |
| Telephone number: |  |
|  | | |
| **Request ADDITION of a drug or device to the list** | | |
| Generic name of drug or device: |  |
| Brand/trade name of drug or device: |  |
| UK launch date: |  |
| Short description of clinical indications. e.g. patient symptoms (max 500 characters): |  |
| BNF category (please specify the BNF category, expected BNF category or n/a if not known): |  |
| Estimated cost and usage per year: |  |
| Any relevant guidance? – for example, NICE (please include weblinks if available): |  |
| Any other supporting Information (Inc. references): |  |
|  | |
| **Request REMOVAL of a drug or device to the list** | | |
| Generic name of drug or device: |  |
| Brand/trade name of drug or device: |  |
| Reason for removal: |  |

Once complete please send to [pricing@england.nhs.uk](mailto:pricing@england.nhs.uk)

1. The Health and Care Bill includes provisions to rename the National Tariff Payment System the ‘NHS Payment Scheme’. However, no changes are expected to the way high cost drugs and devices are excluded from nationally calculated prices. This document refers to the national tariff but any changes to the exclusion lists would apply to the national payment system enforced for 2023/24. [↑](#footnote-ref-1)